Cyteir Therapeutics, Inc. (CYT)

NASDAQ: CYT · IEX Real-Time Price · USD
1.69
+0.07 (4.32%)
Feb 3, 2023, 4:00 PM EST - Market closed
4.32%
Market Cap 59.89M
Revenue (ttm) n/a
Net Income (ttm) -49.08M
Shares Out 35.44M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 92,073
Open 1.64
Previous Close 1.62
Day's Range 1.57 - 1.71
52-Week Range 1.13 - 7.31
Beta n/a
Analysts Buy
Price Target 5.44 (+221.89%)
Earnings Date Mar 15, 2023

About CYT

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was inc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 40
Stock Exchange NASDAQ
Ticker Symbol CYT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CYT stock is "Buy." The 12-month stock price forecast is $5.44, which is an increase of 221.89% from the latest price.

Price Target
$5.44
(221.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxy...

2 weeks ago - Business Wire

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

5 months ago - Business Wire

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

6 months ago - Business Wire

Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

6 months ago - Business Wire

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

8 months ago - Business Wire

Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

8 months ago - Business Wire

Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

9 months ago - Business Wire

Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

9 months ago - Business Wire

Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

9 months ago - Business Wire

Cyteir Therapeutics Names Adam Veness General Counsel

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

10 months ago - Business Wire

Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

10 months ago - Business Wire

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

11 months ago - Business Wire

Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

11 months ago - Business Wire

Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of Directors

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire

Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire

Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire

Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire

Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire

Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, t...

1 year ago - Business Wire

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire

Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire

Cyteir Therapeutics Selected to Join Russell 2000® Index

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer w...

1 year ago - Business Wire

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, ...

1 year ago - Business Wire